2024-11-18 02:42:00
Bridge Biotherapeutics Discloses Interim Results from the First Cohort of Phase 2a Study of BBT-401, an Experimental Drug for Ulcerative Colitis
Corporate/ 2023-07-23
Bridge Biotherapeutics Discloses Interim...

The Interim data showed that 3 out of 9 evaluable patients on BBT-401 responded with more than 30% reduction in Total Mayo Score or 25% redu...

Merck and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Corporate/ 2023-07-23
Merck and Pfizer Receive US FDA Breakthr...

Not intended for US-,Canada- and UK-based media - Breakthrough Therapy Designation and Submission based on positive Phase III JAVELIN Bladde...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release